ACTINIUM PHARMACEUTICALS overview
ACTINIUM PHARMACEUTICALS
> Analyses
Thank you
Reply
Chart
Londinia
has published a new analysis.
- 0
- 72959
- 15111
- 0
Timeframe : Daily - Simple chart
Status : IN PROGRESS...
The strong short-term decline in ACTINIUM PHARMACEUTICALS calls into question the currently slightly bullish basic trend. A trend reversal is likely. As long as the price remains below the resistance
ACTINIUM PHARMACEUTICALS
> News
PR Newswire published a news.
Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting
•
•
PR Newswire •
Stocks •
More ACTINIUM PHARMACEUTICALS news...
Thank you
Chart
ACTINIUM PHARMACEUTICALS
> News
PR Newswire published a news.
Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
•
•
PR Newswire •
Stocks •
More ACTINIUM PHARMACEUTICALS news...
Thank you
Chart
ACTINIUM PHARMACEUTICALS
> News
PR Newswire published a news.
Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
•
•
PR Newswire •
Stocks •
More ACTINIUM PHARMACEUTICALS news...
Thank you
Chart
Statistics
- Analyses : 17
- Followers : 2